Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Thursday
Mar082012

Discovery Labs ($DSCO): Fourth time's a charm !

Discovery Laboratories (DSCO) gains on Surfaxin approval : Discovery Laboratories Inc. (NASDAQ: DSCO) gained as much as 44% yesterday (Wednesday) before closing up 9%, or $0.33, to $4.08 after FDA approved Surfaxin lucinactant late Tuesday to prevent respiratory distress syndrome in premature infants. Discovery plans to launch the humanized lung surfactant in the U.S. late this year. We can't recall if this is the fourth or fifth time that Surfaxin went up for approval but Kudos to the DSCO team for hanging in there to get it done.

Conclusion: Discovery (DSCO) is worth watching now. While this is a niche product, there is a real market opportunity in prematurely born infants and we believe with the great need that specialty and big pharma has DSCO could be acquired at a premium, so we would be inclined to own shares and see what happens.

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Athersys Announces Private Placement Financing - $ATHX | Main | Dendreon ($DNDN) : Gets whacked based on a competitors Good News »